Geropharm pharmaceutical company (Saint Petersburg) filed a lawsuit with the Intellectual Property Rights Court regarding the cancellation of the extension of one of the Novo Nordisk’s invention.
Danish pharmaceutical manufacturer Novo Nordisk A/S has filed an application for registration of an invention with Rospatent in 2004. The applicant received patent No. 2352581 for the drug insulin degludec in 2009.
The patent was due to expire in 2024, but recently Rospatent decided to extend it until 2029.
Geropharm intends to achieve the abolition of this decision.
Geropharm is one of the largest pharmaceutical manufacturers in Russia and has the only full-cycle industrial production of genetically engineered insulin in the country
In Russia, according to the Ministry of Health, 4.8 million people suffer from diabetes.